Obinutuzumab beta (Bejescin) vs PF-05280586
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Follicular Lymphoma
Shared mechanism: CD20 · full Follicular Lymphoma pipeline
Obinutuzumab beta (Bejescin)
Marketed by Beijing Mabworks Biotech Co., Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
PF-05280586
Marketed by Pfizer
NCT02213263 · Phase 3 · completed
The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.
Reported efficacy
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)
Result source: NCT02213263
Results for Follicular Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Obinutuzumab beta (Bejescin): no structured comparison results are available for Follicular Lymphoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obinutuzumab beta (Bejescin)'s landscape · PF-05280586's landscape